Edition:
United Kingdom

Immunovia AB (publ) (IMMNOV.ST)

IMMNOV.ST on Stockholm Stock Exchange

148.40SEK
16 Sep 2019
Change (% chg)

-- (--)
Prev Close
148.40kr
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
19,094
52-wk High
188.80kr
52-wk Low
128.00kr

Latest Key Developments (Source: Significant Developments)

Immunovia Q2 Loss Before Tax Widens To SEK 29.9 Million
Friday, 23 Aug 2019 

Aug 23 (Reuters) - Immunovia AB (publ) ::Q2 NET SALES SEK 154,000 VERSUS SEK 44,000 YEAR AGO.Q2 LOSS BEFORE TAX 29.9 MILLION VERSUS LOSS SEK 26,1 MILLION YEAR AGO.IMMRAY PANCAN-D, CO'S BLOOD-BASED TEST FOR EARLY DETECTION OF PANCREATIC CANCER, IS NOW SET FOR Q3 2020 LAUNCH.  Full Article

Immunovia's CEO Sells 48,000 Immunovia Shares
Wednesday, 19 Jun 2019 

June 19 (Reuters) - Immunovia AB (publ) ::IMMUNOVIA'S CEO MATS GRAHN SELLS 48,000 IMMUNOVIA SHARES TO A SWEDISH INSTITUTIONAL INVESTOR.TRANSACTION WAS CARRIED OUT AT A PRICE OF SEK 168 PER SHARE.MATS GRAHN, CEO OF IMMUNOVIA, TODAY ANNOUNCED THAT HE HAS SOLD 48,000 SHARES OF IMMUNOVIA, CORRESPONDING TO 11.6% OF HIS HOLDING IN IMMUNOVIA.  Full Article

Immunovia Appoints Pete Salzmann As CEO
Wednesday, 5 Jun 2019 

June 5 (Reuters) - Immunovia AB (publ) ::IMMUNOVIA AB (PUBL) - APPOINTS PETE SALZMANN AS CHIEF EXECUTIVE OFFICER.  Full Article

Immunovia Announces Results From Immray PanCan-D Optimization Work
Monday, 3 Jun 2019 

June 3 (Reuters) - Immunovia AB (publ) ::IMMUNOVIA ANNOUNCES EXCELLENT RESULTS ACROSS ALL SYMPTOMATIC RISK GROUPS FROM IMMRAY PANCAN-D OPTIMIZATION WORK.IMMRAY PANCAN-D BLOOD-BASED TEST FOR EARLY DETECTION OF PANCREATIC CANCER NOW SET FOR Q3 2020 LAUNCH.OPTIMIZATION WORK FOR COMMERCIAL VERSION OF IMMRAY PANCAN-D BEEN SUCCESSFUL AND SIGNIFICANTLY IMPROVED PERFORMANCE OF TEST.TEST NOW SHOWS ACCURACIES HIGHER THAN 90% AND EVEN UP TO 98% IN DIFFERENTIATING PDAC OF STAGE I THROUGH IV VERSUS LARGE SYMPTOMATIC RISK GROUPS.  Full Article

Immunovia: Additional US Centers To Validate Immraytm Pancan-D Test Designed
Thursday, 16 May 2019 

May 16 (Reuters) - Immunovia AB (publ) ::IMMUNOVIA - CENTERS IN NEW YORK AND CHICAGO TO VALIDATE IMMRAYTM PANCAN-D TEST DESIGNED FOR EARLY DETECTION OF PANCREATIC CANCER.  Full Article

Immunovia Q3 Net Loss Widens To SEK 17.4 Mln
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Immunovia AB (publ) ::IMMUNOVIA'S TARGET IS TO ACHIEVE TURNOVER OF SEK 250-300 MILLION BY 2022 BASED ON SELF-PAY FOR IMMRAY™ PANCAN -D.TO ACHIEVE TOTAL TURNOVER, INCLUDING PAYMENT VIA SELF-PAY AND COST REMUNERATION FROM INSURANCE SYSTEMS, OF SEK 800-1,000 MILLION BY 2024.Q3 NET LOSS SEK 17.4 MILLION VERSUS LOSS SEK 11.6 MILLION YEAR AGO.JULY-SEPT NET SALES AT SEK 85,000 VERSUS SEK 27,000 YEAR AGO.  Full Article

Immunovia Q1 Operating Loss Widens To SEK 17.4 Million
Friday, 27 Apr 2018 

April 27 (Reuters) - IMMUNOVIA AB (PUBL) ::Q1 NET SALES SEK 112,000 VERSUS SEK 28,000 YEAR AGO.COMPANY HAS A TARGET OF ACHIEVING TURNOVER OF SEK 250-300 MILLION BY 2021.TARGET OF TOTAL TURNOVER OF SEK 800-1,000 BY 2023.Q1 OPERATING LOSS SEK 17.4 MILLION VERSUS LOSS SEK 7.9 MILLION YEAR AGO.  Full Article

Immunovia Aims To Reach SEK 250-300 Million In Turnover In 2021​
Monday, 12 Mar 2018 

March 12 (Reuters) - IMMUNOVIA AB (PUBL) ::IMMUNOVIA ANNOUNCES FINANCIAL TARGETS.‍GOAL IS TO REACH SEK 250-300 MILLION IN TURNOVER IN 2021​.‍GOAL IS TO REACH TURNOVER OF SEK 800-1,000 MILLION IN 2023​.‍EXPECTS FIRST REVENUES FROM SELF-PAY SALES DURING Q4 OF 2018​.TARGET OF SEK 250-300 MILLION IN TURNOVER IN 2021,.TO ACHIEVE A TURNOVER OF SEK 250-300 MILLION IN 2021 BASED ON SELF-PAY FOR IMMRAY™ PANCAN-D..  Full Article

Immunovia AB Q4 Net Sales Sek ‍​ 26,000 Versus Sek 106,000 Year Ago
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - IMMUNOVIA AB ::Q4 NET SALES SEK ‍​ 26,000 VERSUS SEK 106,000 YEAR AGO.Q4 PRETAX LOSS SEK ‍​ 15.3 MILLION VERSUS LOSS SEK 5.4 MILLION YEAR AGO.  Full Article

Immunovia Q3 net loss widens to SEK 11.6 mln‍​
Friday, 10 Nov 2017 

Nov 10 (Reuters) - IMMUNOVIA AB (PUBL) :NET SALES FOR Q3 2017 WERE SEK 27 THOUSAND (5 K)‍​.THE NET LOSS FOR Q3 2017 WAS SEK 11,589 THOUSAND (-4,048 K)‍​.  Full Article